Annals of Oncology 12:S3-S8, 2001
© 2001 European Society for Medical Oncology
Symposium Article |
The Basic Biology of HER2
Department of Biological Regulation, The Weizmann Institute of Science Rehovot, Israel
Correspondence to Y Yarden, PhD Department of Biological Regulation The Weizmann Institute of Science Rehovot 76100 Israel E-mail: yosef.yarden{at}weizmann.ac.il
Human epidermal growth factor receptors (HER/erbB) constitute a family of four cell surface receptors involved in transmission of signals controlling normal cell growth and differentiation. A range of growth factors serve as ligands, but none is specific for the HER2 receptor. HER receptors exist as both monomers and dimers, either homo- or heterodimers. Ligand binding to HER1, HER3 or HER4 induces rapid receptor dimerization, with a marked preference for HER2 as a dimer partner. Moreover, HER2-containing heterodimers generate intracellular signals that are significantly stronger than signals emanating from other HER combinations. In normal cells, few HER2 molecules exist at the cell surface, so few heterodimers are formed and growth signals are relatively weak and controllable. When HER2 is overexpressed multiple HER2 heterodimers are formed and cell signaling is stronger, resulting in enhanced responsiveness to growth factors and malignant growth. This explains why HER2 overexpression is an indicator of poor prognosis in breast tumors and may be predictive of response to treatment. HER2 is a highly specific and promising target for new breast cancer treatments. The recombinant human anti-HER2 monoclonal antibody (rhuMAb-HER2, trastuzumab, Herceptin) induces rapid removal of HER2 from the cell surface, thereby reducing its availability to heterodimers and reducing oncogenicity.
breast cancer, HER2 (erbB-2, neu), network, signal transduction, tumor growth, tyrosine phosphorylation
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  N. Dhani, D. Tu, D. J. Sargent, L. Seymour, and M. J. Moore Alternate Endpoints for Screening Phase II Studies Clin. Cancer Res., March 15, 2009; 15(6): 1873 - 1882. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. A. Fromm, S. A. S. Johnson, and D. L. Johnson Epidermal Growth Factor Receptor 1 (EGFR1) and Its Variant EGFRvIII Regulate TATA-Binding Protein Expression through Distinct Pathways Mol. Cell. Biol., October 15, 2008; 28(20): 6483 - 6495. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Vazquez-Martin, C. Oliveras-Ferraros, R. Colomer, J. Brunet, and J. A. Menendez Low-scale phosphoproteome analyses identify the mTOR effector p70 S6 kinase 1 as a specific biomarker of the dual-HER1/HER2 tyrosine kinase inhibitor lapatinib (Tykerb(R)) in human breast carcinoma cells Ann. Onc., June 1, 2008; 19(6): 1097 - 1109. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Andre, R. Nahta, R. Conforti, T. Boulet, M. Aziz, L. X. H. Yuan, F. Meslin, M. Spielmann, G. Tomasic, L. Pusztai, et al. Expression patterns and predictive value of phosphorylated AKT in early-stage breast cancer Ann. Onc., February 1, 2008; 19(2): 315 - 320. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Sidera, M. Gaitanou, D. Stellas, R. Matsas, and E. Patsavoudi A Critical Role for HSP90 in Cancer Cell Invasion Involves Interaction with the Extracellular Domain of HER-2 J. Biol. Chem., January 25, 2008; 283(4): 2031 - 2041. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. R. Kumar, T. P. Quinn, and S. L. Deutscher Evaluation of an 111In-Radiolabeled Peptide as a Targeting and Imaging Agent for ErbB-2 Receptor Expressing Breast Carcinomas Clin. Cancer Res., October 15, 2007; 13(20): 6070 - 6079. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I Duran, R Salazar, O Casanovas, V Arrazubi, E Vilar, L. Siu, J Yao, and J Tabernero New drug development in digestive neuroendocrine tumors Ann. Onc., August 1, 2007; 18(8): 1307 - 1313. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Kubetzko, E. Balic, R. Waibel, U. Zangemeister-Wittke, and A. Pluckthun PEGylation and Multimerization of the Anti-p185HER-2 Single Chain Fv Fragment 4D5: EFFECTS ON TUMOR TARGETING J. Biol. Chem., November 17, 2006; 281(46): 35186 - 35201. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. G. Bache, S. Stuffers, L. Malerod, T. Slagsvold, C. Raiborg, D. Lechardeur, S. Walchli, G. L. Lukacs, A. Brech, and H. Stenmark The ESCRT-III Subunit hVps24 Is Required for Degradation but Not Silencing of the Epidermal Growth Factor Receptor Mol. Biol. Cell, June 1, 2006; 17(6): 2513 - 2523. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P Kauraniemi and A Kallioniemi Activation of multiple cancer-associated genes at the ERBB2 amplicon in breast cancer. Endocr. Relat. Cancer, March 1, 2006; 13(1): 39 - 49. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F Castiglioni, E Tagliabue, M Campiglio, S M Pupa, A Balsari, and S Menard Role of exon-16-deleted HER2 in breast carcinomas. Endocr. Relat. Cancer, March 1, 2006; 13(1): 221 - 232. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Kassouf, C. P.N. Dinney, G. Brown, D. J. McConkey, A. J. Diehl, M. Bar-Eli, and L. Adam Uncoupling between Epidermal Growth Factor Receptor and Downstream Signals Defines Resistance to the Antiproliferative Effect of Gefitinib in Bladder Cancer Cells Cancer Res., November 15, 2005; 65(22): 10524 - 10535. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y.-B. Cheung, C. Goh, J. Thumboo, K.-S. Khoo, and J. Wee Variability and Sample Size Requirements of Quality-of-Life Measures: A Randomized Study of Three Major Questionnaires J. Clin. Oncol., August 1, 2005; 23(22): 4936 - 4944. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. R. Fantin, M. J. Berardi, H. Babbe, M. V. Michelman, C. M. Manning, and P. Leder A Bifunctional Targeted Peptide that Blocks HER-2 Tyrosine Kinase and Disables Mitochondrial Function in HER-2-Positive Carcinoma Cells Cancer Res., August 1, 2005; 65(15): 6891 - 6900. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L A Bazley and W J Gullick The epidermal growth factor receptor family Endocr. Relat. Cancer, July 1, 2005; 12(Supplement_1): S17 - S27. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Ispolatov, A. Yuryev, I. Mazo, and S. Maslov Binding properties and evolution of homodimers in protein-protein interaction networks Nucleic Acids Res., June 27, 2005; 33(11): 3629 - 3635. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. U. Buzdar, N. K. Ibrahim, D. Francis, D. J. Booser, E. S. Thomas, R. L. Theriault, L. Pusztai, M. C. Green, B. K. Arun, S. H. Giordano, et al. Significantly Higher Pathologic Complete Remission Rate After Neoadjuvant Therapy With Trastuzumab, Paclitaxel, and Epirubicin Chemotherapy: Results of a Randomized Trial in Human Epidermal Growth Factor Receptor 2-Positive Operable Breast Cancer J. Clin. Oncol., June 1, 2005; 23(16): 3676 - 3685. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. N. Hortobagyi In Reply: J. Clin. Oncol., April 20, 2005; 23(12): 2868 - 2869. [Full Text] [PDF]
|
|
|
|
|
|
E. Andreopoulou, P. J. Ross, M. E. R. O'Brien, H. E. R. Ford, K. Priest, T. Eisen, A. Norton, S. Ashley, and I. E. Smith The palliative benefits of MVP (mitomycin C, vinblastine and cisplatin) chemotherapy in patients with malignant mesothelioma Ann. Onc., September 1, 2004; 15(9): 1406 - 1412. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. M. Hommelgaard, M. Lerdrup, and B. van Deurs Association with Membrane Protrusions Makes ErbB2 an Internalization-resistant Receptor Mol. Biol. Cell, April 1, 2004; 15(4): 1557 - 1567. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. S. Kapoor, Y. Zhan, G. R. Johnson, and D. M. O'Rourke Distinct Domains in the SHP-2 Phosphatase Differentially Regulate Epidermal Growth Factor Receptor/NF-{kappa}B Activation through Gab1 in Glioblastoma Cells Mol. Cell. Biol., January 15, 2004; 24(2): 823 - 836. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. T. Chung and R. W. Carlson Goals and Objectives in the Management of Metastatic Breast Cancer Oncologist, December 1, 2003; 8(6): 514 - 520. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. B. Schiffer, S. Gebhard, C. K. Heimerdinger, A. Heling, J. Hast, U. Wollscheid, B. Seliger, B. Tanner, S. Gilbert, T. Beckers, et al. Switching Off HER-2/neu in a Tetracycline-Controlled Mouse Tumor Model Leads to Apoptosis and Tumor-Size-Dependent Remission Cancer Res., November 1, 2003; 63(21): 7221 - 7231. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Birrane, J. Chung, and J. A. A. Ladias Novel Mode of Ligand Recognition by the Erbin PDZ Domain J. Biol. Chem., January 10, 2003; 278(3): 1399 - 1402. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Kari, T. O. Chan, M. Rocha de Quadros, and U. Rodeck Targeting the Epidermal Growth Factor Receptor in Cancer: Apoptosis Takes Center Stage Cancer Res., January 1, 2003; 63(1): 1 - 5. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O. Tikhomirov and G. Carpenter Identification of ErbB-2 Kinase Domain Motifs Required for Geldanamycin-induced Degradation Cancer Res., January 1, 2003; 63(1): 39 - 43. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. M. Graves, J. Han, and H. S. Earp III Transactivation of the EGF Receptor: Is the PDGF Receptor an Unexpected Accomplice? Mol. Interv., July 1, 2002; 2(4): 208 - 212. [Abstract] [Full Text] [PDF]
|
|